Bayhill Therapeutics News
Most Popular Bayhill Therapeutics Story
Genentech forges $350M deal for Bayhill diabetes program
San Mateo, CA-based Bayhill Therapeutics is pocketing a $25 million upfront fee and stands to gain up to $325 million in milestones from a new licensing deal with Genentech covering its early-stage Read more...
Latest Headlines
- June 15, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
